[Market Movement Analysis] BillionToOne Surges on September 17: New Liquid Biopsy, Cancer Detection, and Molecular Diagnostics

1. On September 1, the company launched the Northstar Origin liquid biopsy add-on project and expanded the Northstar Select testing panel from 84 genes to 102 genes, broadening applications in tumor tissue origin prediction and cancer detection.
2. On August 18, the company announced a prospective study covering 2,212 pregnant carriers, with a pregnancy outcome collection rate of 98.6%. The UNITY fetal risk screening sensitivity was 94.4%, providing clinical data support for its noninvasive prenatal testing product.
3. On August 5, the company released its quarterly results as of June 30, reporting revenue of $109.4 million, a year-on-year increase of 64%. Gross profit was $77.1 million, with the gross profit margin rising from 65% to 70%. The company reaffirmed its 2026 revenue guidance of $450 million to $465 million.

(Disclaimer: This content is generated based on publicly available information collected by AI technology and is for reference only. It does not constitute investment advice.)